<DOC>
	<DOCNO>NCT02490514</DOCNO>
	<brief_summary>This open-label , non-randomized , retrospective-prospective , non-interventional study evaluate efficacy safety Mircera patient stage III-IV chronic kidney disease ( CKD ) dialysis . Patients receive open-label treatment Mircera 12 month dose determine investigator .</brief_summary>
	<brief_title>A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Acidosis , Renal Tubular</mesh_term>
	<criteria>Patients stage IIIV CKD dialysis , include renal transplant patient , receive erythropoiesisstimulating agent ( ESA ) treatment ESAnaive Patients require dialysis within 12 month start Mircera therapy Patients whose life expectancy great 12 month Mircera initiation Patients &gt; /= 18 year &lt; /= 75 year age Patients female childbearing potential must use effective contraception method Patients contraindication ESA treatment ( example , hypersensitivity , noncontrolled hypertension others accord local SmPC ) Patients give write informed consent local regulation allow require Patients stage III stage V CKD Poorly control hypertension Active malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>